Tumor Biology

, Volume 34, Issue 2, pp 847–851 | Cite as

PTEN protein expression in malignant pleural mesothelioma

  • Vijay Agarwal
  • Anne Campbell
  • Kate L. Beaumont
  • Lynn Cawkwell
  • Michael J. Lind
Research Article


Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitutive activation of AKT resulting in cell survival and proliferation. Small studies reported that PTEN protein expression is rarely lost in mesothelioma whilst a larger study demonstrated prognostic significance of PTEN protein expression status with absence in 62 % of cases. We aimed to analyse PTEN protein expression in mesothelioma. Immunohistochemical analysis was performed in 86 archival mesothelioma samples to determine the PTEN protein expression status and statistical analysis was performed to identify any prognostic significance. Mesothelial cells in normal pleura demonstrated positive staining for PTEN protein and served as a positive reference. For mesothelioma samples, the expression of PTEN protein was scored as 0 (negative), 1 (intensity less than that of positive normal pleura reference slide) and 2 (intensity equal to or greater than positive normal pleura reference slide). A total of 23/86 (26.7 %) scored 0, 23/86 (26.7 %) scored 1 and 40/86 (46.5 %) scored 2 for PTEN expression. Univariate analysis demonstrated that lack of PTEN expression was not associated with survival. PTEN protein expression was undetectable in 26.7 % of mesothelioma samples; however, no prognostic significance was identified. Absence of PTEN protein may result in activation of the PI3K/AKT/MTOR pathway. Targeting this pathway with inhibitors further downstream of PTEN may provide a potential therapeutic target in selected patients.


AKT Immunohistochemistry Mesothelioma MTOR pathway PTEN 



This work was supported by the Peel Medical Research Trust. The sponsors played no role in study design, analysis of data or manuscript preparation.

Conflicts of interest

No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.


  1. 1.
    Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the british population: a case–control study. Br J Cancer. 2009;100:1175–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718–21.PubMedGoogle Scholar
  3. 3.
    Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29:2–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Tan E, Warren N, Darnton AJ, Hodgson JT. Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer. 2010;103:430–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The european mesothelioma epidemic. Br J Cancer. 1999;79:666–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:73–5.PubMedGoogle Scholar
  7. 7.
    Grosso F, Scagliotti GV. Systemic treatment of malignant pleural mesothelioma. Future Oncol. 2012;8:293–305.PubMedCrossRefGoogle Scholar
  8. 8.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRefGoogle Scholar
  9. 9.
    van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the european organisation for research and treatment of cancer lung cancer group and the national cancer institute of canada. J Clin Oncol. 2005;23:6881–9.PubMedCrossRefGoogle Scholar
  10. 10.
    van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2010;78(2):92–111.PubMedCrossRefGoogle Scholar
  11. 11.
    Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 2001;34:279–87.PubMedCrossRefGoogle Scholar
  12. 12.
    O’Kane SL, Cawkwell L, Campbell A, Lind MJ. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer. 2005;41:1645–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, mmac1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Li DM, Sun H. Tep1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997;57:2124–9.PubMedGoogle Scholar
  16. 16.
    Ali IU, Schriml LM, Dean M. Mutational spectra of pten/mmac1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999;91:1922–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the pten/mmac1/tep1 gene in human lung cancers. Genes Chromosome Cancer. 1998;22:152–6.CrossRefGoogle Scholar
  18. 18.
    Wang SI, Parsons R, Ittmann M. Homozygous deletion of the pten tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998;4:811–5.PubMedGoogle Scholar
  19. 19.
    Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of pten/mmac1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998;58:204–9.PubMedGoogle Scholar
  20. 20.
    Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of pten and the 10q23 region in primary prostate carcinomas. Oncogene. 1998;16:1743–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, et al. Mutation of the pten (mmac1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998;58:29–33.PubMedGoogle Scholar
  22. 22.
    Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in pten are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935–40.PubMedGoogle Scholar
  23. 23.
    Risinger JI, Hayes AK, Berchuck A, Barrett JC. Pten/mmac1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–8.PubMedGoogle Scholar
  24. 24.
    Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene pten/mmac1 in primary breast carcinomas. Cancer Res. 1997;57:3657–9.PubMedGoogle Scholar
  25. 25.
    Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, et al. Germline mutations in the pten/mmac1 gene in patients with Cowden disease. Hum Mol Genet. 1997;6:1383–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the pten gene in cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Hollander MC, Blumenthal GM, Dennis PA. Pten loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289–301.PubMedCrossRefGoogle Scholar
  28. 28.
    Maehama T, Dixon JE. The tumor suppressor, pten/mmac1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated akt/pkb activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24:6080–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase ii study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J Clin Oncol. 2007;25:2406–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. Pten expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008;33:502–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the pi3k-akt pathway in human malignant mesothelioma cells. Mol Med Rep. 2009;2:181–8.PubMedGoogle Scholar
  33. 33.
    Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998;95:5246–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Salmena L, Carracedo A, Pandolfi PP. Tenets of pten tumor suppression. Cell. 2008;133:403–14.PubMedCrossRefGoogle Scholar
  35. 35.
    Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet. 2001;27:222–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:E59.PubMedCrossRefGoogle Scholar
  37. 37.
    Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene pten. Br J Cancer. 1998;78:1296–300.PubMedCrossRefGoogle Scholar
  38. 38.
    Mohiuddin I, Cao X, Ozvaran MK, Zumstein L, Chada S, Smythe WR. Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of akt phosphorylation. Ann Surg Oncol. 2002;9:310–6.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Vijay Agarwal
    • 1
    • 2
    • 3
  • Anne Campbell
    • 1
    • 4
  • Kate L. Beaumont
    • 1
  • Lynn Cawkwell
    • 1
    • 2
    • 5
  • Michael J. Lind
    • 1
    • 2
    • 3
  1. 1.Cancer Biology Proteomics GroupPostgraduate Medical Institute of the University of HullHullUK
  2. 2.Hull York Medical SchoolHullUK
  3. 3.Queens Centre for Oncology and HaematologyHull and East Yorkshire NHS TrustHullUK
  4. 4.Histopathology DepartmentHull and East Yorkshire NHS TrustHullUK
  5. 5.Research LaboratoriesCastle Hill HospitalHullUK

Personalised recommendations